Loading cancer entity…
Loading cancer entity…
Clinical trials
4,033 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (699)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03701217 | Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML | unknown | Phase 2 / Phase 3 | 220 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT03642236 | Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 22, 2018 |
| NCT02333838 | Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies(TBF-Cord) | unknown | Phase 2 | 31 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT03573596 | Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment(DASTOP2) | unknown | Phase 2 | 134 | Amsterdam UMC, location VUmcOTHER | 7 | Jun 29, 2018 | clinicaltrials |
| NCT02576301 | Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS(AML) | unknown | Phase 1 / Phase 2 | 105 | Mateon TherapeuticsINDUSTRY | 1 | Jun 4, 2018 | clinicaltrials |
| NCT01451268 | Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)(PANOBEST) | unknown | Phase 1 / Phase 2 | 62 | Johann Wolfgang Goethe University HospitalOTHER | 1 | Mar 20, 2018 | clinicaltrials |
| NCT03381781 | Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations | unknown | Phase 2 | 100 | Li JunminOTHER | 1 | Jan 4, 2018 | clinicaltrials |
| NCT03091933 | Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)(GLIDE) | unknown | Phase 1 / Phase 2 | 20 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT03356080 | DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess | unknown | Phase 2 | 50 | Shanghai Tong Ren HospitalOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT03256071 | Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT | unknown | Phase 2 / Phase 3 | 90 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 21, 2017 | clinicaltrials |
| NCT03241199 | The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia | unknown | Phase 2 | 15 | The University of Hong KongOTHER | 1 | Aug 8, 2017 | clinicaltrials |
| NCT02899286 | Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia | unknown | Phase 2 | 25 | Bio-Cancer Treatment International LimitedINDUSTRY | 1 | Jul 28, 2017 | clinicaltrials |
| NCT02802267 | Efficacy Study of Inecalcitol With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy | unknown | Phase 2 | 110 | Hybrigenics CorporationINDUSTRY | 2 | Jul 2, 2017 | clinicaltrials |
| NCT03205267 | Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients(BODO) | unknown | Phase 2 | 127 | University of BonnOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01520558 | CNDO-109-AANK for AML in First Complete Remission (CR1) | unknown | Phase 1 / Phase 2 | 12 | Coronado Biosciences, Inc.INDUSTRY | 1 | Jun 29, 2017 | clinicaltrials |
| NCT03080922 | High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML | unknown | Phase 1 / Phase 2 | 10 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT03053206 | A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid Leukemia | unknown | Phase 2 | 84 | All India Institute of Medical SciencesOTHER | 0 | Feb 15, 2017 | clinicaltrials |
| NCT03045627 | Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients | unknown | Phase 2 | 120 | Shandong UniversityOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT02742727 | CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02944162 | CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02949570 | Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study(ICT10) | unknown | Phase 2 | 54 | Hybrigenics CorporationINDUSTRY | 1 | Oct 31, 2016 | clinicaltrials |
| NCT01758367 | Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT02848183 | Optimal Treatment Strategy Based on for Pediatric AML | unknown | Phase 2 | 350 | Samsung Medical CenterOTHER | 1 | Jul 28, 2016 | clinicaltrials |
| NCT01146262 | Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM)(CD lam) | unknown | Phase 1 / Phase 2 | 5 | Nantes University HospitalOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT01690065 | Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML(NICE-BORA) | unknown | Phase 2 | 46 | Ulsan University HospitalOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT02422719 | Radotinib as 3rd or Later Line Therapy in CP-CML(REVITAL) | unknown | Phase 2 | 73 | Ulsan University HospitalOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT01864902 | Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33(CART33) | unknown | Phase 1 / Phase 2 | 10 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT02502968 | BL-8040 Addition to Consolidation Therapy in AML Patients(BLAST) | unknown | Phase 2 | 194 | Dr. Petra TschanterOTHER | 1 | Sep 21, 2015 | clinicaltrials |
| NCT01802450 | Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase(DASAPOST) | unknown | Phase 2 | 18 | PETHEMA FoundationOTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT02511340 | A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients | unknown | Phase 2 | 167 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 30, 2015 | clinicaltrials |
| NCT02261779 | Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible(TCP-AML) | unknown | Phase 1 / Phase 2 | 16 | Martin-Luther-Universität Halle-WittenbergOTHER | 1 | Jul 7, 2015 | clinicaltrials |
| NCT01369368 | Treatment of Acute Leukemia Relapse After Allotransplantation | unknown | Phase 1 / Phase 2 | 20 | University of BergenOTHER | 1 | Jun 24, 2015 | clinicaltrials |
| NCT00885508 | A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q(GFM-Chimio-Rev) | unknown | Phase 2 | 85 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Apr 24, 2015 | clinicaltrials |
| NCT01298934 | LBH589 (Panobinostat) for the Treatment of Myelofibrosis | unknown | Phase 1 / Phase 2 | 22 | Ronald HoffmanOTHER | 1 | Mar 6, 2015 | clinicaltrials |
| NCT02275663 | Azacytidine Plus FLAG for Relapsed or Refractory AML | unknown | Phase 2 | 37 | King Fahad Medical CityOTHER_GOV | 1 | Jan 6, 2015 | clinicaltrials |
| NCT01800643 | Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation | unknown | Phase 2 / Phase 3 | 100 | Hospital Israelita Albert EinsteinOTHER | 1 | Dec 3, 2014 | clinicaltrials |
| NCT00668421 | CEP-701 (Lestaurtinib) in Myelofibrosis | unknown | Phase 1 / Phase 2 | 60 | Ronald HoffmanOTHER | 1 | Nov 26, 2014 | clinicaltrials |
| NCT02007811 | Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination(B-cell therapy) | unknown | Phase 1 / Phase 2 | 15 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Mar 26, 2014 | clinicaltrials |
| NCT00242515 | T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) | unknown | Phase 1 / Phase 2 | 16 | National University Hospital, SingaporeOTHER | 1 | Jan 8, 2014 | clinicaltrials |
| NCT00451711 | Intermittent Liposomal Amphotericin B Primary Prophylaxis | unknown | Phase 2 | 60 | Bayside HealthOTHER_GOV | 1 | Dec 16, 2013 | clinicaltrials |
| NCT01488344 | Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 140 | University Hospital MuensterOTHER | 1 | Dec 11, 2013 | clinicaltrials |
| NCT01950611 | Proteasome Inhibition in Acute Promyelocytic Leukemia(PIAPL) | unknown | Phase 2 | 30 | Christian Medical College, Vellore, IndiaOTHER | 1 | Sep 25, 2013 | clinicaltrials |
| NCT00036712 | Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation | unknown | Phase 2 | 80 | Medical College of WisconsinOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT01887561 | Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial | unknown | Phase 2 | 100 | Kanto CML Study GroupOTHER | 1 | Jun 27, 2013 | clinicaltrials |
| NCT01503502 | A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia | unknown | Phase 2 | 150 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 10, 2013 | clinicaltrials |
| NCT01809392 | Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | unknown | Phase 2 / Phase 3 | 15 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 12, 2013 | clinicaltrials |
| NCT01037556 | PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia | unknown | Phase 1 / Phase 2 | 50 | Proacta, IncorporatedINDUSTRY | 1 | Aug 31, 2012 | clinicaltrials |
| NCT01627132 | Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial | unknown | Phase 2 | 50 | Shimousa Hematology Study GroupOTHER | 1 | Jun 25, 2012 | clinicaltrials |
| NCT00111345 | Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents | unknown | Phase 2 / Phase 3 | 550 | University Hospital MuensterOTHER | 1 | May 23, 2012 | clinicaltrials |
| NCT00887042 | Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML | unknown | Phase 1 / Phase 2 | 35 | The Korean Society of Pediatric Hematology OncologyNETWORK | 1 | Mar 26, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Oct 9, 2018source: clinicaltrials